Combating infections in neutropenic patients.
In febrile neutropenic patients, most of whom have cancer, immediate, albeit empiric, antibiotic therapy reduces infectious morbidity and mortality. With respect to definitive therapy, it is stressed that isolate patterns are changing, even as new antibiotics are becoming available. Issues such as single-agent versus combination therapy, as well as preventive strategies, are reviewed.
Pizzo
P A
PA
Infectious Diseases Section, National Cancer Institute, Bethesda.
D000380:Agranulocytosis / Q000150:complications*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D001424:Bacterial Infections / Q000150:complications / Q000517:prevention & control*; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005334:Fever / Q000209:etiology; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D009181:Mycoses / Q000150:complications / Q000517:prevention & control*; D009369:Neoplasms / Q000150:complications; D009503:Neutropenia / Q000150:complications* / Q000209:etiology
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D002511:Cephalosporins